<DOC>
	<DOCNO>NCT02821026</DOCNO>
	<brief_summary>Islet transplantation relatively new procedure use people difficult control Type 1 diabetes . Insulin produce cell ( islet ) isolate pancreas decease organ donor . After cell carefully prepare , islet transplant patient 's body . These transplanted islet may produce insulin patient . Patient may able reduce eliminate need insulin injection unknown period time . Patients receive islet transplant may need stay powerful immunosuppressive drug long islet remain alive working . These drug help prevent immune system attack transplant islet . Under current standard care procedure , islet transplant patient 's liver . The investigator learn cell survive current procedure lose around time transplant . Therefore study , investigator study new transplant procedure may help prevent islet cell loss . The new procedure involve transplant islet omental pouch instead liver . The omentum large apron-like fold membrane inside abdomen drape intestine . This study test see omental islet transplantation safe effective . Standard immunosuppressive medicine ( anti-thymocyte globulin , tacrolimus , mycophenolic acid , sirolimus , etanercept ) use study prevent rejection islet . This study collaborative research University Miami , study protocol use . Recruitment Edmonton continue subject [ N=6 ] need study transplant . All subject study receive islet transplant use study procedure .</brief_summary>
	<brief_title>Omental Islet Transplant</brief_title>
	<detailed_description>BACKGROUND Current islet transplantation portal vein liver show unique ability islet stabilize blood glucose level prevent severe hypoglycemia select group subject type 1 diabetes . The main limitation islet transplantation need systemic immunosuppression maintain function loss islet function time . Additionally , many study demonstrate current site transplantation liver ideal site due several factor . These factor include ( 1 ) significant liver inflammation follow islet infusion ; ( 2 ) potential life-threatening procedure-related complication bleed thrombosis ; ( 3 ) high level immunosuppressive drug GI toxins liver contributing islet toxicity ; ( 4 ) inability retrieve islet infusion ; ( 5 ) development graft dysfunction number recipient intrahepatic allogeneic autologous islet . Based premise , development clinical protocol implantation islet omentum desirable goal . As attempt maximize engraftment islet cell cluster onto omentum , implantation site promote islet adherence omental peritoneal layer avoid cell pelleting . Dr. Alejandro 's team University Miami recently perform series experiment animal model diabetes assess feasibility transplant pancreatic islet omentum use plasma-thrombin gel . With approach , islets re-suspended either donor autologous plasma distribute omental pouch ( created suture ) avoid pelleting . Cell adherence achieve addition clinical-grade recombinant human thrombin reacts plasma create biocompatible , degradable gel contain islet graft . The investigator outline initial patient trial 6 subject , base clinical judgment extensive experience clinical islet transplantation trial . If initial safety efficacy satisfactory ( adverse event related transplantation efficacy 2 3 first transplanted subject ) , investigator transplant 3 additional subject . OBJECTIVES Primary Objective Safety : To demonstrate safety islet transplantation omental pouch site treatment subject type 1 diabetes ( T1D ) . Secondary Objective Efficacy : To demonstrate efficacy islet transplantation omental pouch site treatment T1D subject hypoglycemia unawareness history severe hypoglycemic episode . Primary Endpoints The primary safety endpoint demonstrate patient safety throughout stage trial . The primary efficacy endpoint proportion subject HbA1c ≤6.5 % 1 year AND free severe hypoglycemic event Day 28 Day 365 , inclusive , islet transplant . Secondary Endpoints Secondary efficacy endpoint : At 75±7 , 365 ± 14 , 730 ± 14 day follow islet transplant ( ) : percent reduction insulin requirement ; HbA1c ; Mean Amplitude Glycemic Excursions ( MAGE ) ; Lability Index ( LI ) ; Ryan hypoglycemia severity ( HYPO ) score ; Clarke score ; number severe hypoglycemic episode ; basal ( fast ) 90-min glucose c-peptide derive mixed-meal tolerance test ( MMTT ) ; beta-score ; C-peptide creatinine ratio ; acute insulin response glucose ( AIRglu ) , insulin sensitivity , disposition index derive insulin-modified frequently-sampled intravenous glucose tolerance ( FSIGT ) test ; glucose variability hypoglycemia duration derive continuous glucose monitoring system® ( CGMS ) ; Quality life ( QOL ) measure : EuroQol five dimension questionnaire ( EQ-5D ) , Hypoglycemia Fear Survey ( HFS ) , SF-36v2 , Diabetes Distress scale ) . Secondary safety endpoint : Safety , include incidence post-transplant infection , malignancy , morbidity , adverse event ( AEs ) ( e.g. , increase body weight hypertension ) associate conventional immunosuppression . Renal function measure serum creatinine , glomerular filtration rate ( GFR ) relevant laboratory parameter . Lipid profile ( triglyceride , total cholesterol , LDL cholesterol , HDL cholesterol ) time . At 75 ± 7 365 ± 14 day follow islet transplant , two year follow final islet transplant : incidence severity AEs relate islet transplant procedure include : bleeding ( &gt; 2 g/dL decrease hemoglobin concentration ) ; wind complication ( infection subsequent hernia ) ; torsion omentum ; gastrointestinal obstruction ; abscess ; cyst ; need surgical intervention . The incidence severity AEs related immunosuppression include : allergy ; reduction GFR ; addition intensification antihyperlipidemic therapy ; gastrointestinal toxicity ; neutropenia , anemia , thrombocytopenia ; viral , bacterial , fungal infection ; benign malignant neoplasm . The incidence immune sensitization define presence anti-HLA antibody absent prior transplantation . The incidence discontinuation immunosuppression . PROCEDURES Prior transplantation , patient screen , qualify , list transplant , sign inform consent form . At time suitable islet preparation become available , patient receive allogeneic islet cell place omental pouch . The detail surgical procedure address Question 5.0 . Islet transplant perform Anti-Thymocyte Globulin ( ATG , Thymoglobulin® ) induction immunosuppression ( 5 dos , day -2 prior transplant day 2 post-transplant ) . Maintenance mycophenolate mofetil ( MMF ) therapy ( 1-2 g/day BID dosing ) start Day -1 pre-transplant . Tacrolimus administer orally twice daily Day 1 post-transplant maintain trough level 10-12 ng/mL 3 month , 6-10 ng/mL thereafter . Etanercept give IV islet transplant ( 50 mg ) , 25 mg ( subcutaneously ) post-operative day ( POD ) +3 , +7 +10 . FOLLOW UP Subject undergo 24-month follow-up period follow islet transplant . 19 study visit first year transplant , 4 study visit 2nd year transplant .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . Male female patient age 18 65 year age . 2 . Ability provide write informed consent . 3 . Mentally stable able comply procedure study protocol . 4 . Clinical history compatible T1D onset disease &lt; 40 year age , insulindependence &gt; 5 year time enrollment , sum subject age insulindependent diabetes duration ≥28 . 5 . Absent stimulate cpeptide ( &lt; 0.3 ng/mL ) response MMTT ( Boost® 6 mL/kg body weight maximum 360 mL ; another product equivalent caloric nutrient content may substitute Boost® ) measure 60 90 min start consumption . 6 . Involvement intensive diabetes management , define selfmonitoring glucose value less mean three time day average week administration three insulin injection day insulin pump therapy . Such management must direction endocrinologist , diabetologist , diabetes specialist , least 3 clinical evaluation 12 month prior study enrollment . 7 . At least one episode severe hypoglycemia 12 month prior study enrollment . 8 . Reduced awareness hypoglycemia define Clarke score 4 OR A HYPO score great equal 90th percentile ( 1047 ) screen period ; OR Marked glycemic lability characterize wide swing blood glucose ( BG ) despite optimal diabetes therapy define LI score great equal 90th percentile ( 43 mmol/L2/h·wk1 ) screening period ; OR A composite Clarke score 3 less HYPO score great equal 75th percentile ( 423 ) LI great equal 75th percentile ( 329 ) screening period . 1 . Body Mass Index ( BMI ) &gt; 30 kg/m2 patient weight ≤50 kg . 2 . Insulin requirement &gt; 1.0 IU/kg/day &lt; 15 U/day . 3 . HbA1c &gt; 10 % . 4 . Untreated proliferative diabetic retinopathy . 5 . Blood Pressure : systolic blood pressure ( SBP ) &gt; 160 mmHg diastolic blood pressure ( DBP ) &gt; 100 mmHg . 6 . Measured glomerular filtration rate &lt; 80 mL/min/1.73 m2 calculate use subject 's measure serum creatinine Chronic Kidney Disease Epidemiology Collaboration ( CKDEPI ) equation1 Modification Diet Renal Disease [ MDRD ] study estimation formula ) . Strict vegetarian ( vegan ) calculate GFR &lt; 70 mL/min/1.73m2 exclude . The absolute ( raw ) GFR value use subject body surface area &gt; 1.73m2 7 . Presence history macroalbuminuria ( &gt; 300mg/g creatinine ) . 8 . Presence history panelreactive antiHLA antibody background flow cytometry . 9 . For female subject : Serum urine Positive pregnancy test , presently breastfeed , unwillingness use effective contraceptive measure duration study 4 month discontinuation . For male subject : intent procreate duration study within 4 month discontinuation unwillingness use effective measure contraception . If sexually active , subject must use least two medically accept method birth control follow list : oral contraceptive , Norplant® , DepoProvera® , intrauterine device ( IUD ) , barrier device spermicide . Condoms use alone acceptable . Instead male condom , acceptable use female condom one method woman list . 10 . Presence history active infection include hepatitis B , hepatitis C , HIV , tuberculosis ( TB ) Subjects laboratory evidence active infection exclude even absence clinical evidence active infection . 11 . Negative screen EpsteinBarr Virus ( EBV ) IgG determination . 12 . Invasive aspergillus , histoplasmosis , coccidioidomycosis infection within one year prior study enrollment . 13 . Any history malignancy except completely resect squamous basal cell carcinoma skin . 14 . Known active alcohol substance abuse . 15 . Baseline Hb low limit normal local laboratory ; lymphopenia ( &lt; 1,000/µL ) , neutropenia ( &lt; 1,500/µL ) , thrombocytopenia ( platelet &lt; 100,000/µL ) . Participants lymphopenia allow investigator determine additional risk obtain clearance hematologist . 16 . A history Factor V deficiency . 17 . Any coagulopathy medical condition require longterm anticoagulant therapy ( e.g. , warfarin ) transplantation ( lowdose aspirin treatment allow ) patient international normalized ratio ( INR ) &gt; 1.5 . 18 . Severe coexist cardiac disease , characterize one condition : 1. recent myocardial infarction ( within past 6 month ) . 2. evidence ischemia functional cardiac exam within last year . 3. leave ventricular ejection fraction &lt; 30 % . 19 . Persistent elevation liver function test time study entry . Persistent serum glutamicoxaloacetic transaminase ( SGOT [ AST ] ) , serum glutamate pyruvate transaminase ( SGPT [ ALT ] ) , Alk Phos total bilirubin , value &gt; 1.5 time normal upper limit exclude patient . 20 . Symptomatic cholecystolithiasis . 21 . Acute chronic pancreatitis . 22 . Symptomatic peptic ulcer disease . 23 . Severe unremitting diarrhea , vomit , gastrointestinal disorder potentially interfere ability absorb oral medication . 24 . Hyperlipidemia despite medical therapy ( fast lowdensity lipoprotein [ LDL ] cholesterol &gt; 130 mg/dL ( 3.36 mmol/L ) , treat untreated ; and/or fast triglyceride &gt; 200 mg/dL ( 2.26 mmol/L ) ) . 25 . Receiving treatment medical condition require chronic use systemic steroid , except use ≤5 mg prednisone daily , equivalent dose hydrocortisone , physiological replacement . 26 . Treatment antidiabetic medication insulin within 4 week enrollment . 27 . Use investigational agent within 4 week enrollment . 28 . Administration live attenuate vaccine ( ) within 2 month enrollment . 29 . Any medical condition , opinion investigator , interfere safe participation trial . 30 . Treatment immunosuppressive regimen time enrollment . 31 . A previous islet transplant . 32 . A previous pancreas transplant , unless graft fail within first week due thrombosis , follow pancreatectomy transplant occur 6 month prior enrollment . 33 . Inflammatory bowel disease . 34 . History intestinal obstruction . 35 . Previous major abdominal surgery . 36 . History peritonitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>